How do you present the trade off between a small chance of a sustained response for a new drug at the expense of potential worsening quality of life?  

Since we now have an increasing number of treatments at our disposal, this becomes an ever more frequent conversation in oncology. This question gets at several Shared Decision Making (SDM) model steps. Usually in this scenario, there are not routine standard of care options and highlighting th...